Sales broadly higher at GSK

Sales increased across GlaxoSmithKline’s three business groups in 2017, but the company expressed caution for the year ahead owing to uncertainty about the timing of the market entry of a generic competitor for its respiratory medicine Advair.

Full text available to subscribers only. Click here for information on subscribing to MedNous.


United Kingdom